Bruker Announces Progress in Advanced Methods and Software Tools for 4D High-Throughput and Ultra-High Sensitivity Proteomics
By MICHAEL BARRETT ANDERSEN
Bruker and Evosep announce further progress in high-sensitivity, high-throughput plasma-proteomics
WASHINGTON, March 4, 2019 /PRNewswire/ — At the 15th Annual Conference of the US Human Proteome Organization (www.ushupo.org), Bruker and Evosep announce further progress in high-sensitivity, high-throughput plasma-proteomics using the timsTOF Pro mass spectrometer connected to an Evosep One low-flow chromatography system.
###
For the full press release, please see here.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information: www.bruker.com.
About Evosep
Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 100 times more robust and 10 times faster than todays’ alternatives. Proteomics is about the study of proteins in a biological mechanism, both their individual function and their combined interactions. For clinical proteomics the goal is to be able to quickly and efficiently compare a biological sample against a profile panel of selected proteins in order to deliver a diagnose / verdict of healthy or diseased (within given statistical margins). Such a profile is typically called a biomarker and for official approval, it must be demonstrated successfully on a large population. This calls for fast sample processing and because such clinical samples, in the form of blood or biopsies, are much more crude that the relatively clean cell cultures used in basic research, very robust protocols and consumables are also required.
###
(1) “A novel LC system embeds analytes in pre-formed gradients for rapid, ultra-robust proteomics”, Nicolai Bache et al., Molecular & Cellular Proteomics August 13, 2018: http://www.mcponline.org/content/early/2018/08/13/mcp.TIR118.000853